U.S. Markets open in 8 hrs 46 mins

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.5500-0.2800 (-5.80%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.8300
Bid4.0000 x 1300
Ask4.6000 x 900
Day's Range4.3300 - 4.8800
52 Week Range3.4500 - 31.7600
Avg. Volume206,022
Market Cap22.286M
Beta (5Y Monthly)6.58
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A

    Towercrest Capital Management Buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, ...

    Newtown, PA, based Investment company Towercrest Capital Management (Current Portfolio) buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, Invesco S&P 500 Equal Weight ETF, Impel NeuroPharma Inc, Kala Pharmaceuticals Inc, sells Vanguard FTSE Emerging Markets ETF, International Business Machines Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Towercrest Capital Management.

  • Benzinga

    Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients

    Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute myeloid leukemia and myelodysplastic syndromes (AML/MDS). The study met its primary endpoint of identification of an active dose level for advanced studies. The Company plans to submit the data for publication later this year. Of seven evaluable relapsed AML patients treated in Cohort 6, four showed stabilization of their leukemias. Of those four patients with disease stabilization, three patients lived over 246 days, over 261 days, and over 281 days, respectively, and one progressed after a month. Two relapsed AML patients, who experienced stabilization of their leukemia, achieved partial remission and subsequently a complete remission. No partial or complete remissions have been observed at APVO436 dose levels either lower or higher than the Cohort 6 dose level. APVO436 was generally well tolerated and demonstrated a favorable side effect profile, including the absence of severe or prolonged neutropenia, an often serious condition associated with CD123-targeting therapies. Price Action: APVO shares are up 9.7% at $27.71 during the market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaVistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94BDyadic's Stock Jumps On COVID-19 Vaccine Development Pact In India© 2021 Benzinga does not provide investment advice. All rights reserved.